-+ 0.00%
-+ 0.00%
-+ 0.00%

On January 8, Luye Pharmaceutical Group announced that the Drug Evaluation Center of the China National Drug Administration has officially accepted the marketing application for the new indications of the Group's Class 1 innovative drug Ruoxinlin®, which is intended to be used to treat generalized anxiety disorder.

Zhitongcaijing·01/08/2026 23:49:09
Listen to the news
On January 8, Luye Pharmaceutical Group announced that the Drug Evaluation Center of the China National Drug Administration has officially accepted the marketing application for the new indications of the Group's Class 1 innovative drug Ruoxinlin®, which is intended to be used to treat generalized anxiety disorder.